Cellectis (NASDAQ:CLLS) Announces Earnings Results

Cellectis (NASDAQ:CLLS) announced its quarterly earnings results on Monday. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03), Zacks reports. The firm had revenue of $18.05 million during the quarter, compared to analysts’ expectations of $5.00 million. Cellectis had a negative net margin of 401.83% and a negative return on equity of 78.90%. During the same quarter in the previous year, the firm posted ($0.31) EPS.

Cellectis Stock Up 2.8 %

Shares of NASDAQ:CLLS traded up $0.05 during trading hours on Tuesday, reaching $1.81. The stock had a trading volume of 40,776 shares, compared to its average volume of 47,794. The stock has a market capitalization of $100.60 million, a price-to-earnings ratio of -1.36 and a beta of 3.10. The firm’s 50 day moving average is $2.09 and its 200-day moving average is $2.28. Cellectis has a 1 year low of $1.75 and a 1 year high of $3.77. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.92 and a current ratio of 1.92.

Analyst Upgrades and Downgrades

CLLS has been the subject of several recent analyst reports. Barclays reduced their price objective on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a research note on Tuesday. StockNews.com started coverage on Cellectis in a report on Tuesday. They set a “sell” rating for the company.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.